Tenax Therapeutics has the Financial Strength Rank of 7.
Good Sign:
Tenax Therapeutics Inc shows strong financial strength.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Tenax Therapeutics did not have earnings to cover the interest expense.
As of today, Tenax Therapeutics's Altman Z-Score is 0.00.
Competitive Comparison
For the Biotechnology subindustry, Tenax Therapeutics's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tenax Therapeutics Financial Strength Distribution
For the Biotechnology industry and Healthcare sector, Tenax Therapeutics's Financial Strength distribution charts can be found below:
* The bar in red indicates where Tenax Therapeutics's Financial Strength falls into.
Tenax Therapeutics Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Tenax Therapeutics's Interest Expense for the
months ended in Dec. 2023 was $-0.00 Mil. Its Operating Income for the
months ended in Dec. 2023 was $-3.34 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil.
Tenax Therapeutics's Interest Coverage for the quarter that ended in Dec. 2023 is
| Tenax Therapeutics did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Tenax Therapeutics's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Tenax Therapeutics has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tenax Therapeutics (Tenax Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
101 Glen Lennox Drive, Suite 300, Chapel Hill, NC, USA, 27517
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction.
Executives
| Robyn Hunter |
director |
95 SAWYER ROAD, SUITE 110, WALTHAM MA 02453 |
| Eliot M Lurier |
officer: Interim CFO |
C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560 |
| Chrisopher Thomas Giordano |
director, officer: CEO |
C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560 |
| Armistice Capital, Llc |
director |
510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
| Armistice Capital Master Fund Ltd. |
director |
C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
| Steven Boyd |
director |
510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
| June Sherie Almenoff |
director |
C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY 10019 |
| Michael H. Davidson |
director |
OMTHERA PHARMACEUTICALS, INC., 707 STATE ROAD, PRINCETON NJ 08540 |
| Declan Doogan |
director |
C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510 |
| Stuart Rich |
officer: Chief Medical Officer |
C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560 |
| Illya Keith Maher |
director |
C/O ARMISTICE CAPITAL, 510 MADISON AVE., 7TH FLOOR, NEW YORK NY 10022 |
| Ronald R Blanck |
director |
2001 WALNUT HILL LANE, IRVING TX 75038 |
| Gerald T Proehl |
director |
|
| James P. Mitchum |
director |
C/O NEPHROGENEX, INC., 79 T.W. ALEXANDER DRIVE, RESEARCH TRIANGLE PARK NC 27709 |
| John P Kelley |
officer: Chief Executive Officer |
C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
Tenax Therapeutics (Tenax Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TENX has been successfully added to your